ReviewPLoS genetics2016
Exploiting Genetic Interference for Antiviral Therapy.
Review in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine.Journal of advanced research · 2026Review
- Intracellular interactions shape antiviral resistance outcomes in poliovirus via eco-evolutionary feedback.Nature ecology & evolution · 2026Article
- Quantifying the Inhibitory Efficacy of HIV-1 Therapeutic Interfering Particles at a Single CD4 T-Cell Resolution.Viruses · 2025Article
- Intracellular interactions shape antiviral resistance outcomes in poliovirus via eco-evolutionary feedback.bioRxiv : the preprint server for biology · 2025Article
- Exploiting social traits for clinical applications in bacteria and viruses.npj antimicrobials and resistance · 2025Review
- Viral gene drive spread during herpes simplex virus 1 infection in mice.Nature communications · 2024Article
- Mathematical model calibrated toiScience · 2024Article
- Antiviral Activity of Oligonucleotides Targeting the SARS-CoV-2 Genomic RNA Stem-Loop Sequences within the 3'-End of the ORF1b.Pathogens (Basel, Switzerland) · 2022Article
- Effects of Carbon Nanomaterials andPharmaceutics · 2022Review
- Virus-like Particles: Measures and Biological Functions.Viruses · 2022Review
- Targeting Conserved Sequences Circumvents the Evolution of Resistance in a Viral Gene Drive against Human Cytomegalovirus.Journal of virology · 2021Article
- Article
- Ten recent insights for our understanding of cooperation.Nature ecology & evolution · 2021Review
- Article
- Would the interference phenomenon be applied as an alternative option for prophylaxis against COVID-19?BioImpacts : BI · 2021Article
- Propensity of a picornavirus polymerase to slip on potyvirus-derived transcriptional slippage sites.The Journal of general virology · 2019Article
- Article
- Transmissible Viral Vaccines.Trends in microbiology · 2018Review
- Antivirals against animal viruses.Biochemical pharmacology · 2017Review
- Collective Infectious Units in Viruses.Trends in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Rapidly evolving viruses are a major threat to human health. Such viruses are often highly pathogenic (e.g., influenza virus, HIV, Ebola virus) and routinely circumvent therapeutic intervention through mutational escape. Error-prone genome replication generates heterogeneous viral populations that rapidly adapt to new selection pressures, leading to resistance that emerges with treatment. However, population heterogeneity bears a cost: when multiple viral variants replicate within a cell, they can potentially interfere with each other, lowering viral fitness. This genetic interference can be exploited for antiviral strategies, either by taking advantage of a virus's inherent genetic diversity or through generating de novo interference by engineering a competing genome. Here, we discuss two such antiviral strategies, dominant drug targeting and therapeutic interfering particles. Both strategies harness the power of genetic interference to surmount two particularly vexing obstacles-the evolution of drug resistance and targeting therapy to high-risk populations-both of which impede treatment in resource-poor settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.